References
- Acton G., Dailey J.W., Morris S.W., McNatt L. Evidence for an endogenous factor interfering with antagonist binding at the muscarinic cholinergic receptor. Eur. J. Pharmacol. 1979; 58: 343–344
- Barlow R.B., Burston K.N., Vis A. Three types of muscarinic receptors?. Br. J. Pharmacol. 1980; 68: 141–142P
- Brunner F., Kukovetz W.R. Characterization of guinea-pig cardiac muscarinic receptors by radioligand dissociation kinetics. Eur. J. Pharmacol. 1988; 151: 249–257
- Buckley N.J., Bonner T.I., Brann M.R. Localization of a family of muscarinic receptor mRNAs in rat brain. J. Neurosci. 1988; 12: 4646–4652
- Buckley N.J., Bonner T.I., Buckley C.M., Brann M.R. Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol. Pharm. 1989; 35: 469–476
- Clague R.U., Eglen A.C., Strachen A.C., Whiting R.L. Action of agonists and antagonists at muscarinic receptors present in ileum and atria in vitro. Br. J. Pharmacol. 1985; 86: 163–170
- Costa E., Corda M.G., Epstein B., Forchetti C., Guidotti A. GABA-benzodiazepine interactions. The benzodiazepines: From molecular biology to clinical practice, E. Costa. Raven, New York 1983; 117–136
- Creazzo T.L., Hartzell H.C. Reduction of muscarinic acetylcholine receptor number and affinity by an endogenous substance. J. Neurochem. 1985; 45: 710–718
- Diaz-Arrastia R., Ashizawa T., Appel S.H. Endogenous inhibitor of ligand binding to the muscarinic acetylcholine receptor. J. Neurochem. 1985; 44: 622–628
- El-Fakahany E.E. Intact cells: A model for studying receptor binding and function. Clinical pharmacology, Vol. 13, Receptor pharmacology and function, M. Williams, R.A. Glennon, P.B. Timmermans. Dekker, New York 1989; 695–715
- Hammer R., Giraldo E., Schiavi G.B., Monferini E., Ladinsky H. Binding profile of a novel cardioselective muscarinic receptor antagonist, AF-DX 116, to membranes of peripheral tissues and brain in the rat. Life Sci. 1986; 38: 1653–1662
- Kubo T., Fukuda K., Mikami A., Maeda A., Takahashi H., Mishina M., Haga T., Haga K., Ichiyama A., Kangawa K., Kojima M., Matsuo H., Hirose T., Numa S. Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor. Nature 1988; 323: 411–416
- Lundberg J.M., Hedlund B., Bartfai T. Vasoactive intestinal polypeptide enhances muscarinic ligand binding in cat submandibular salivary gland. Nature 1982; 295: 147–149
- McPherson G.A. A practical computer based approach to the analysis of radioligand binding experiments. Comput. Programs Biomed. 1983; 17: 107–114
- Munson P.J., Rodbard D. LIGAND: A versatile computerized approach for the characterization of ligand binding systems. Anal. Biochem. 1980; 107: 220–239
- Mutschuler E., Lambrecht G. Selective muscarinic agonists and antagonists in functional tests. Trends Pharmacol. Sci. 1984; 5: 39–44, Suppl
- Nathanson N.M. Molecular properties of the muscarinic acetylcholine receptor. Annu. Rev. Neurosci. 1987; 10: 195–236
- Peralta E.G., Ashkenazi A., Winslow J.W., Smith D.H., Ramachandran J., Capon D.J. Distinct promary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J. 1987; 6: 3923–3929
- Rosenthal H.E. A graphic method for the determination and presentation of binding parameters in complex systems. Anal. Biochem. 1967; 20: 525–532
- Schudt C., Auriga C., Kinder B., Birdsall N.J.M. The binding of [3H]telenzepine to muscarinic acetylcholine receptors in calf forebrain. Eur. J. Pharmacol. 1988; 145: 87–90
- Stein R., Pinkas-Kramarski R., Sokolovsky M. Cloned M1 muscarinic receptors mediate both adenylate cyclase inhibition and phosphoinositide turnover. EMBO J. 1988; 7: 3031–3035
- van Koppen C.J., Sokolovsky M. Evidence for an endogenous factor involved in maintenance of pirenzepine high-affinity binding in rat brain stem. Biochem. Biophys. Res. Commun. 1988; 157: 42–47